Onconetix, Inc. (ONCO) Stock Price & Analysis
Onconetix, Inc. (ONCO) fell 6.25% to USD 0.95 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.
ONCO last closed at USD 1.01; the session ranged USD 0.94–1.01 on volume of 315,708 shares. Market capitalization is $1.09M, with a 52-week range of USD 0.91–361.25 (NCM). Source: Nexqual, June 10, 2026 at 02:36 UTC.
Key Statistics (as of June 10, 2026 at 02:36 UTC)
| Price | USD 0.95 |
|---|---|
| Change | ▼ 6.25% (down) |
| Previous Close | USD 1.01 |
| Open | USD 0.98 |
| Day Range | USD 0.94 – 1.01 |
| 52-Week Range | USD 0.91 – 361.25 |
| Volume | 315,708 shares |
| Market Cap | $1.09M |
| Exchange | NCM |
Technical Analysis (ONCO)
Nexqual's technical model rates ONCO "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 19.57 (oversold) |
| vs SMA50 | Below (USD 6) |
| MACD | -1.8 (negative) |
Analyst Ratings (ONCO)
Wall Street analysts rate ONCO "None", per Nexqual as of June 10, 2026 at 02:36 UTC.
| Consensus Rating | None |
|---|
Earnings (ONCO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -52,700.03 vs est -32,300.02 ▼ miss |
| 2023-06-30 | USD -73,100.04 vs est -30,600.02 ▼ miss |
| 2023-03-31 | USD -30,600.02 vs est -34,850.02 ▲ beat |
| 2022-12-31 | USD -27,200.01 vs est -45,050.02 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financials & Fundamentals (ONCO)
| Total Revenue | $735,198 |
|---|---|
| Revenue Growth (YoY) | -78.90% |
| Gross Margin | +79.63% |
| Operating Margin | -9748.80% |
| Profit Margin | +0.00% |
| ROE | -123.28% |
| Debt / Equity | 2.47 |
| Current Ratio | 1.41 |
| Total Cash | $3.72M |
| Total Debt | $289,922 |
| Free Cash Flow | $-6.33M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financial Health Score (ONCO)
Nexqual rates Onconetix, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:36 UTC.
| Growth | Critical — Revenue -79% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$10M |
| Efficiency | Critical — ROE -123%, ROA -25.2% |
Ownership (ONCO)
| Insider Ownership | +0.61% |
|---|---|
| Institutional Ownership | +0.20% |
| Shares Outstanding | 1.15M |
| Float | 10.46M |
| Short % of Float | +4.53% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Leadership (ONCO)
Onconetix, Inc. is led by David Allan White C.A., C.P.A., ICD.D (age 72), Chief Executive Officer, per Nexqual as of June 10, 2026 at 02:36 UTC.
| Chief Executive Officer | David Allan White C.A., C.P.A., ICD.D (age 72) |
|---|---|
| Interim Chief Financial Officer | Karina M. Fedasz (age 52) |
From Onconetix, Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union.
- The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
- It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NIVF | NewGenIvf Group Limited | USD 0.49 | ▼ 22.88% |
| AZTR | Azitra Inc | USD 0.21 | ▲ 0.62% |
| PBM | Psyence Biomedical Ltd. | USD 3.33 | ▼ 5.13% |
| TRNR | Interactive Strength Inc. | USD 0.7 | ▼ 6.21% |
| ATPC | Agape ATP Corporation | USD 3.12 | ▲ 4.7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.